GCTK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GC

Volume

141.94K

Next Earnings

November 12th

Loading chart

GC

GCTKGlucoTrack, Inc. Common Stock

GCTK

Pay with—

Available Balance0.00

GC

Mkt Cap

$846,888

Volume

141.94K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note FinancingE.F. Hutton & Co. served as exclusive financial advisor and placement agent for a strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics, along with a $5.7 million convertible note financing. The transaction creates a publicly traded healthcare platform combining Lōkahi's AI-driven asset sourcing capabilities with Glucotrack's Nasdaq listing, with Lōkahi becoming the operating company and Glucotrack's CBGM business continuing as a subsidiary.GlobeNewswire Inc. · Jul 17, 2026

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public PlatformGlucotrack, Inc. (NASDAQ: GCTK) completed a strategic business combination with Lōkahi Therapeutics, creating a publicly listed platform for identifying and advancing healthcare assets. Lōkahi Therapeutics securityholders will hold approximately 90% of the combined company on a fully diluted basis. Erik Emerson was appointed CEO, while Glucotrack's continuous blood glucose monitoring (CBGM) technology will operate as a separate subsidiary under Paul Goode's leadership. The transaction is supported by a planned private placement financing.GlobeNewswire Inc. · Jul 16, 2026

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlucotrack Inc. (NASDAQ: GCTK) submitted an Investigational Device Exemption (IDE) application to the FDA for its fully implantable continuous blood glucose monitoring (CBGM) technology, targeting U.S. clinical trial launch in H2 2026. The company reported Q1 2026 net loss of $4.3 million versus $6.8 million in Q1 2025, with cash position of $3.9 million as of March 31, 2026. Two peer-reviewed studies supporting the technology's long-term stability and accuracy were published, and the company reduced debt while strengthening its balance sheet.GlobeNewswire Inc. · May 14, 2026

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring TechnologyGlucotrack, Inc. (NASDAQ: GCTK) announced the submission of its Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology. The submission follows years of preclinical development and represents a significant milestone toward clinical evaluation and potential regulatory approval of the long-term implantable glucose monitoring system designed for people with diabetes.GlobeNewswire Inc. · May 7, 2026

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlucotrack reported full year 2025 net loss of $19.4 million, an improvement from $22.6 million in 2024. The company completed a $4.0 million private placement, received three new USPTO patents for its implantable continuous blood glucose monitoring technology, and plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 to launch U.S. clinical trials in the second half of 2026. Cash position improved to $7.4 million from $5.6 million year-over-year.GlobeNewswire Inc. · Mar 30, 2026

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate HighlightsGlucotrack, a medical technology company, reported strong progress in 2024, including advancing its continuous blood glucose monitoring technology from preclinical to clinical stage, strengthening its leadership team, and securing funding to support its growth plans.GlobeNewswire Inc. · Mar 31, 2025

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial OfficerGlucotrack, a medical technology company, has appointed industry veteran Peter C. Wulff as its new Chief Financial Officer. Wulff has over 35 years of financial management experience and will play a key role in the commercialization of Glucotrack's continuous blood glucose monitoring system for people with diabetes.GlobeNewswire Inc. · Jan 29, 2025

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORSDiabetes industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetesGlobeNewswire Inc. · Jun 20, 2024

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSORCompletion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathyGlobeNewswire Inc. · Jun 13, 2024

GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCERutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference.GlobeNewswire Inc. · Jun 10, 2024

to start trading

GC

GCTKGlucoTrack, Inc. Common Stock

GCTK

Pay with—

Available Balance0.00

Your PositionYou don't own any GCTK yet.

Related Tickers

Earnings